Search Results
Jan 20, 2026, 14:17 ET Orion Innovation reconocido en Servicios de Ingeniería de Productos Conectados
Innovation. "Ayudamos a nuestros clientes a traducir su estrategia en ejecución: diseñamos productos fiables, aceleramos los lanzamientos con CI/CD y automatización, y mantenemos el rendimiento mediante el soporte del ciclo de vida a escala global".Orion ofrece software integrado, desde hardware
More news about: Orion Innovation
Jan 20, 2026, 13:25 ET Orion Innovation reconnue dans les services d'ingénierie des produits connectés, évaluation des analystes pour le quatrième trimestre 2025
Nous aidons nos clients à traduire leur stratégie en exécution - en concevant des produits fiables, en accélérant les mises en production grâce à CI/CD et à l'automatisation, et en maintenant les performances grâce à une assistance tout au long du cycle de vie à l'échelle mondiale. »Orion fournit
More news about: Orion Innovation
Jan 20, 2026, 09:56 ET Orion Innovation Recognized in Connected Product Engineering Services, Q4 2025 Analyst Evaluation
Innovation (COI), Orion Innovation. "We help clients translate strategy into execution—engineering reliable products, accelerating releases with CI/CD and automation, and sustaining performance through lifecycle support at global scale." Orion delivers embedded software—from bare‑metal
More news about: Orion Innovation
Jan 20, 2026, 09:53 ET Orion Innovation Recognized in Connected Product Engineering Services, Q4 2025 Analyst Evaluation
Innovation (COI), Orion Innovation. "We help clients translate strategy into execution—engineering reliable products, accelerating releases with CI/CD and automation, and sustaining performance through lifecycle support at global scale." Orion delivers embedded software—from bare‑metal
More news about: Orion Innovation
Jan 20, 2026, 09:00 ET Mountain Commerce Bancorp, Inc. Announces Fourth Quarter 2025 Results and Quarterly Cash Dividend
Brokered CDQwickrate CD
More news about: Mountain Commerce Bancorp, Inc.
Jan 20, 2026, 08:00 ET Ouro Medicines Receives U.S. FDA Fast Track Designation for Gamgertamig in Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
periods of relief and avoid the challenges of treatment with immunosuppressive therapies.With a CD3-targeting arm engineered for the reduced induction of T cell cytokines, referred to as a 'detuned' CD3-targeting arm, gamgertamig is designed to avoid severe immune activation while retaining potency
More news about: Ouro Medicines
Jan 20, 2026, 06:30 ET Columbus McKinnon Announces Offering of Senior Secured Notes
offering of the Notes, together with the proceeds from the sale of Series A Cumulative Convertible Participating Preferred Shares of the Company to CD&R XII Keystone Holdings, L.P. and the New Credit Agreement (as defined below), to finance the Acquisition (including the repayment of Kito Crosby's
More news about: Columbus McKinnon Corporation
Jan 20, 2026, 06:00 ET PEOPLES BANCORP INC. ANNOUNCES FOURTH QUARTER AND ANNUAL RESULTS FOR 2025
10.81 %Return on average tangible equity (c)(d)16.57 %
More news about: Peoples Bancorp Inc.
Jan 17, 2026, 12:00 ET Awful Beautiful Life Resort: 75 Tiny Homes for Fort Rucker by 2026
"A Good Day to Run" and "Second Wind." His breakthrough year was 2002 when Worley's touching ballad "I Miss My Friend," the title tune to his second CD, became his first No. 1 hit. After he spent Christmas 2002 entertaining America's troops in Afghanistan, Kuwait, and Uzbekistan, he came home and wrote
More news about: Awful Beautiful Life Luxury Tiny Home Resort
Jan 16, 2026, 13:43 ET AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.7Epcoritamab
More news about: AbbVie
Jan 16, 2026, 09:52 ET What Non-Standard CDs Should Savers Consider in January 2026? CD Valet Highlights Notable Promotional CDs
success."About CD Valet CD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions nationwide. With tens of thousands of CD offers tracked across the country, CD Valet gives savers a clear view of top rates and helps them explore higher-yield CD options
More news about: CD Valet
Jan 16, 2026, 08:00 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
NSCLC.HLX3901: DLL3 × DLL3 × CD3 × CD28 tetravalent TCE developed on the Company's proprietary TCE platform, featuring longer persistence of activated T cells and greater efficacy in solid tumour treatment.HLX3902: Potential FIC STEAP1 × CD3 × CD28 trispecific TCE developed on the
More news about: Henlius
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Cohort 4, where patients now receive 10μg/kg/day dosing. The trial evaluates GTB-3650 in patients with relapsed or refractory blood cancers expressing CD33, particularly acute myeloid leukemia and high-risk myelodysplastic syndrome. The
More news about: Equity Insider
Jan 15, 2026, 20:00 ET Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
malignancies indications. Leveraging this platform, Antengene has discovered multiple investigational programs:ATG-201 (CD19 x CD3 TCE): ATG-201 is a novel "2+1" CD19-targeted T-cell engager developed on the AnTenGager™ TCE platform for the treatment
More news about: Antengene Corporation Limited
Jan 15, 2026, 17:31 ET Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight
T-lymphocytes. It selectively and rapidly depletes the circulating inflammatory myeloid cells and T cells responsible for disease pathology, while preserving the CD47/SIRPα immune checkpoint pathway. ELA026 is presently in Phase II/III clinical development.The anticipated launch of these emerging therapies
More news about: DelveInsight Business Research, LLP
Jan 15, 2026, 11:18 ET MacWeb Introduces MiniCluster™, On-Demand Bare-Metal Apple Mac mini Clusters for Creative and Technical Workloads
Apple M4 Pro Mac mini systems into a single, private compute cloud for creative pipelines, scientific and technical computing, GitHub runners, and CI/CD and production workflows—without the overhead of virtualization.
More news about: MacWeb
Jan 15, 2026, 10:41 ET Dan Franzese Launches Campaign for Congress in President Trump's Home District in Palm Beach County (Florida's 22nd District)
official launch of his campaign for the U.S. House of Representatives in President Donald J. Trump's home district in Palm Beach County, Florida (FL CD -22), running on a record of business leadership, community service, and conservative values.
More news about: Dan Franzese For Congress 2026
Jan 14, 2026, 23:00 ET JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
maintained strong momentum from 2024 into 2025, with accelerating T‑cell engager (TCE) deals highlighting an inflection point for the company's CD3 platform.The CD3 platform enables bispecific antibodies to retain potent tumor-killing activity against target cells while minimizing cytokine release, optimizing
More news about: WuXi Biologics
Jan 14, 2026, 16:30 ET TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
lines of therapy for patients refractory to anti–CD38 monoclonal antibodies and lenalidomide, commonly used medications in multiple myeloma.The MajesTEC-9 study evaluated TECVAYLI® monotherapy in patients predominantly refractory to anti-CD38 and lenalidomide therapies.1 These
More news about: Johnson & Johnson
Jan 14, 2026, 12:30 ET Cloud Native Computing Foundation Announces Dragonfly's Graduation
widely adopted by many enterprises. Continuous improvements in usability and stability enable the project to support a variety of scenarios, including CI/CD, edge computing, and AI. New challenges are emerging for the distribution of model weights and data in the age of AI. Dragonfly is becoming a key infrastructure
More news about: Cloud Native Computing Foundation
Jan 14, 2026, 12:12 ET Clovity Adds Former CoreTrust CEO Mahesh Shah as Operating Advisor to Accelerate AI-Powered Atlassian Growth in Regulated Sectors
scale.Through AI-powered, use-case-driven innovation, Clovity helps organizations modernize workflows, improve ITSM delivery, accelerate DevSecOps and achieve CI/CD excellence. The company's ecosystem of apps and services empowers clients across federal, SLED and enterprise verticals.Clovity is a
More news about: Clovity
Jan 14, 2026, 09:17 ET Columbus McKinnon Reiterates Expected Closing of the Kito Crosby Acquisition and Announces the Divestiture of Certain Product Lines
agreement relating to each of the Acquisition and the Divestiture, (7) the dilution caused by the issuance of perpetual convertible preferred equity to CD&R, (8) the possibility that the Acquisition or the Divestiture may be more expensive to complete than anticipated, including as a result of unexpected
More news about: Columbus McKinnon Corporation
Jan 13, 2026, 20:18 ET Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference
CT-P72, a tetravalent bispecific antibody being developed to target human epithelial growth factor receptor 2 (HER2) and cluster of differentiation 3 (CD3)."We have made significant progress and see compelling opportunities ahead. Building on our company's global footprint in biosimilar excellence,
More news about: Celltrion
Jan 13, 2026, 12:33 ET Adimab Records Another Year of Double-Digit Clinical Program Growth
engineering necessary for certain partner-desired formats.T Cell Engagers: Adimab has a highly characterized suite of functional and diverse CD3 and CD28 antibodies (both IgG and VHH binders) to generate bi- and multispecific T cell engagers. Adimab has partnered this program non-exclusively with
More news about: Adimab, LLC
Jan 13, 2026, 01:46 ET Halper Sadeh LLC Encourages SEE, MBCN, GDOT, SEMR Shareholders to Contact the Firm to Discuss Their Rights
Sealed Air Corporation (NYSE: SEE)'s sale to funds affiliated with CD&R for $42.15 in cash per share. If you are a Sealed Air shareholder,
More news about: Halper Sadeh LLP